Phenibut: When Something Sold as a Nootropic Is Actually a Drug

Abstract

Reviews of nootropics generally conclude that side effects are uncommon and rarely serious. That generalisation holds for herbal extracts at ordinary doses and fails completely for at least one compound sold in the same aisle.

Phenibut is a prescription medicine in some countries and a supplement ingredient in others. This article follows a 2024 review in Basic & Clinical Pharmacology & Toxicology documenting what has happened as a result.

We publish it because the category term hides the variation. A shelf labelled nootropics can contain a mushroom extract and a GABA-B agonist with a documented dependence syndrome, and nothing in the labelling distinguishes them.

1.What Phenibut Is

Phenibut is a GABA analogue with activity at GABA-B, GABA-A and β-phenethylamine receptors. It was developed in the 1960s for the Soviet army and remains an approved medicine in former Soviet countries for anxiety, insomnia, post-traumatic stress disorder and alcohol withdrawal.

It is not an approved medication in the United States, and it is prohibited in France, Italy and Lithuania. Its pharmacological class places it alongside compounds prescribed under supervision with attention to dependence — which is what it produces.

2.How It Is Sold

In 2019 the US Food and Drug Administration warned that phenibut cannot legally be sold as a dietary supplement. The review records what followed: it continues to proliferate online, with manufacturers circumventing regulation by not labelling products as supplements, and some dietary supplements found to be adulterated with substantial amounts of it.

One finding deserves to be quoted for what it reveals about enforcement. Of four brands examined, three actually increased their phenibut content despite the 2019 warnings.

The marketing language is the ordinary language of the category — helps balance mood, promotes focus, increased libido. Nothing in it signals that the compound is a prescription anxiolytic elsewhere in the world.

3.The Harm Data

The numbers are specific and they are not small.

On withdrawal: 95.7 per cent of cases of acute phenibut withdrawal required therapeutic intervention. Symptoms include insomnia, anger, psychomotor agitation, anxiety, tremor, muscle pain and palpitations, with severe cases showing delirium and visual hallucinations.

On acute toxicity: life-threatening or disabling effects occurred in 12.6 per cent of cases, with 80 cases — 6.2 per cent — resulting in coma, and three deaths.

On trend: poison centre exposures increased sevenfold between 2015 and 2018, from just over 50 cases annually to more than 350, reaching 1,122 total cases within the monitoring period by 2019.

A withdrawal syndrome requiring intervention in nineteen of every twenty cases is not a side effect profile. It is the profile of a dependence-producing drug.

4.The Dose Problem

The mechanism by which users arrive at harm is tolerance, and the numbers illustrate it starkly.

Intoxication has been documented at doses as low as 1,000 mg per day over periods shorter than ten days. Among 105 users, mean reported doses averaged 2,430 mg with a standard deviation of 1,620 mg, and some consumed 9,000 mg daily. The review documents one patient ingesting 50,000 mg per day.

A fiftyfold spread between a dose that intoxicates and a dose someone has escalated to describes a compound with no usable margin for self-directed use, taken without medical supervision by people who bought it as a supplement.

5.What the Authors Recommend, and Why It Is Not Prohibition

Their proposals are pragmatic. Add phenibut to standard drug screening panels, since its absence from routine screening often prevents appropriate diagnosis — clinicians cannot treat what they cannot detect. Develop accepted treatment strategies for phenibut-associated toxicity. And restrict availability cautiously.

That last point is the interesting one. Abrupt banning risks hospitalisations among dependent users and proliferation of a black market, so the authors argue that since controlling online marketing seems unrealistic, effort should focus on screening and treatment.

Their closing formulation gives the review its title: a drug with one too many buts to allow it to continue in its stealthy flight below regulatory radars.

6.The General Lesson

There is a related case in the same literature. A 2024 review of Panax notoginseng addresses pharmacological aspects alongside toxicological issues — a botanical, widely sold, with a toxicology section serious enough to warrant its own review.

The pattern is that regulatory category and pharmacological reality come apart. Something sold as a supplement may be a prescription medicine elsewhere, may be an unapproved drug where it is sold, or may be an adulterant in a product that does not list it.

The practical questions this suggests are narrow and worth asking of anything in this category. Is this compound a medicine in any jurisdiction? Has any regulator issued a warning about it? Does it produce tolerance — and therefore escalation? Those three questions separate the mushroom extract from the GABA-B agonist far better than the shelf does.

Editorial Comment

MindHeaven® does not use phenibut or any related compound, and none of our formulations contains an ingredient with a documented dependence syndrome. We would not consider one.

If you are taking phenibut regularly, the most important information in this article is that stopping abruptly is itself dangerous — withdrawal required intervention in the overwhelming majority of documented cases. That is a matter for a doctor, and it is worth saying to someone who bought the substance believing it was a supplement.